Log in to your Inderes Free account to see all free content on this page.

Diamyd Medical

7.8

SEK

+1.43 %

Less than 1K followers

DMYD B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

+1.43%

-4.77%

-57.43%

-52.04%

-41.59%

-16.74%

-53.13%

-54.58%

+161.37%

Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.

Market cap

1.01B SEK

Turnover

2.01M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

25.6.

2025

Interim report Q3'25

8.10.

2025

Annual report '25

All

Press releases

ShowingAll content types

Regulatory press release20 hours ago

Diamyd Medical AB: Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment

Regulatory press release4/14/2025, 11:10 AM

Diamyd Medical AB: Diamyd Medical publishes prospectus with regards to the rights issue

Press release4/9/2025, 5:07 PM

Carnegie Access: Diamyd Medical: Steady progression towards major inflection point – Q2 review

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release4/9/2025, 6:15 AM

Diamyd Medical AB: Quarterly Report 2 24/25

Regulatory press release3/21/2025, 11:10 AM

Diamyd Medical AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue

Press release3/20/2025, 5:21 AM

Carnegie Access: Diamyd Medical: Aiming for GMP certification in 2025

Regulatory press release3/19/2025, 1:40 PM

Diamyd Medical AB: Diamyd Medical plans for GMP Certification in 2025

Regulatory press release3/17/2025, 12:45 PM

Diamyd Medical AB: Diamyd Medical highlights clinical benefits of C-peptide preservation at ATTD 2025

Regulatory press release3/13/2025, 1:25 PM

Diamyd Medical AB: Diamyd Medical advances AI-powered screening for Type 1 Diabetes within the ASSET Project

Regulatory press release3/10/2025, 7:45 AM

Diamyd Medical AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue

Regulatory press release2/28/2025, 1:45 PM

Diamyd Medical AB: The Board of Directors in Diamyd Medical has resolved on a rights issue of approximately SEK 208 million

Regulatory press release2/20/2025, 3:15 PM

Diamyd Medical AB: Diamyd Medical precision medicine patent for prevention and treatment of autoimmune diabetes to be granted in Mexico

Regulatory press release2/18/2025, 10:40 AM

Diamyd Medical AB: Diamyd[ ]Medical's CFO to leave in 2025

Regulatory press release2/12/2025, 9:40 AM

Diamyd Medical AB: Diamyd[ ]Medical announces expanded financial support from Breakthrough T1D

Regulatory press release1/29/2025, 7:15 AM

Diamyd Medical AB: Quarterly Report 1 24/25

Regulatory press release1/21/2025, 9:35 AM

Diamyd Medical AB: South Korea to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes

Regulatory press release1/13/2025, 7:30 AM

Diamyd Medical AB: Diamyd Medical updates U.S. market potential for Diamyd®

Regulatory press release1/10/2025, 10:40 AM

Diamyd Medical AB: Diamyd Medical confirms key advances toward Accelerated Approval for Diamyd® following FDA Type C Meeting

Regulatory press release1/9/2025, 10:30 AM

Diamyd Medical AB: Renowned immunology investigator, Alice Long, joins Diamyd Medical's Scientific Advisory Board

Regulatory press release1/7/2025, 7:30 AM

Diamyd Medical AB: New publication highlights safety and potential benefits of redosing Diamyd® precision medicine for Type 1 Diabetes

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.